Evidence map›Paper›PMID 42291305›Full record

ArticleFrontiers in cellular and infection microbiology2026

Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles in

Magdalena Kuzioła, Małgorzata Korycka-Machała, Daria Zygała-Pytlos, Bożena Dziadek, Malwina Kawka, Jakub Pawełczyk, Norbert Odolczyk, Piotr Zielenkiewicz, Marcin Słomka, Jarosław Dziadek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Magdalena KuziołaInstitute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.
Małgorzata Korycka-MachałaInstitute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.
Daria Zygała-PytlosInstitute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.
Bożena DziadekDepartment of Molecular Microbiology, University of Łódź, Faculty of Biology and Environmental Protection, Łódź, Poland.
Malwina KawkaDepartment of Molecular Microbiology, University of Łódź, Faculty of Biology and Environmental Protection, Łódź, Poland.
Jakub PawełczykInstitute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.
Norbert OdolczykDepartment of Bioinformatics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
Piotr ZielenkiewiczDepartment of Bioinformatics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
Marcin SłomkaFaculty of Biology and Environmental Protection, University of Łódź, Centre for Digital Biology and Biomedical Science - Biobank Łódź, Łódź, Poland.
Jarosław DziadekInstitute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fluoroquinolones (FQs) are pharmacological cornerstone agents in global tuberculosis (TB) management, critical for both accelerating drug-sensitive regimens and defining the resistance spectrum of multidrug-resistant TB. Methods & Results: To evaluate the therapeutic potential of this class across the mycobacterial spectrum, we conducted a comprehensive phenotypic screening campaign utilizing OTAVA and ECBD pilot-libraries against reference strains of Discussion: We hypothesize that the profound differential in intrinsic susceptibility is at least partially driven by non-target factors. This work supports the continued critical role of FQs in

Indexed as

Antitubercular AgentsFluoroquinolonesMycobacterium abscessusMycobacterium tuberculosisTuberculosisBiofilmsDNA GyraseDrug Resistance, BacterialDrug Resistance, Multiple, BacterialHumansMacrophagesMicrobial Sensitivity TestsMolecular Docking SimulationAntitubercular AgentsDNA GyraseFluoroquinolonesDNA gyrasedrug resistancefluoroquinolonesMycobacterium abscessusMycobacterium tuberculosis

Identifiers

PMID42291305
PMCPMC13253442

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.